The combination tablet included sitagliptin, a dipeptidyl peptidase-4 inhibitor that is Merck's best-selling drug, with sales of nearly $3 billion in the first nine months of 2012, and generic atorvastatin.
via The Heart
via The Heart
The India Cardiology 2.0 Medical Social Media Network
No comments:
Post a Comment